$320,000 is the annual contracted base Alidad Mireskandari will draw as President and Chief Operating Officer of Niki BioSolutions, Inc. (Nasdaq: NIKI), per a September 1, 2026 employment agreement disclosed in an 8-K filed September 4. Of that figure, $35,000 is deferred until the company receives capital-investment proceeds of at least $3,000,000, leaving $285,000 in current cash. The base steps to $350,000 if aggregate capital receipts reach $5,000,000.
The two appointments follow a previously announced merger transaction. Ian Huen takes the chief executive role under a six-month appointment letter effective August 1, 2026, formalized September 1. His monthly base is HKD 210,000, which the filing converts at 7.84 to approximately USD 26,800. The annual run-rate is roughly USD 321,600, though the initial term covers six months and is renewable by mutual agreement. Either party may terminate Huen's appointment on one month's written notice, or the company may do so immediately on the occurrence of specified events.
Compensation at a glance
| Executive | Title | Base | Bonus | Equity |
|---|---|---|---|---|
| Ian Huen | CEO | HKD 210,000/month (~USD 26,800) | Discretionary (Board + Committee) | Share bonuses + options (TBD) |
| Alidad Mireskandari | President & COO | $320,000/year ($285,000 until $3M raise) | Up to 50% of base | 20,000 RSUs + 800,000 options |
Mireskandari's equity package includes 20,000 restricted stock units that vested immediately at merger close, plus options on 800,000 shares of Niki common stock under the company's 2026 Equity Incentive Plan, subject to vesting conditions in the agreement. Huen's share bonuses and option grant under the Share Option Plan remain subject to Board and Compensation Committee approval, with amounts and vesting schedules not yet set.
Niki BioSolutions is incorporated in Delaware and listed on the Nasdaq Capital Market. The company operates from 116 Village Boulevard, Suite 200, Princeton, NJ, a new address since the entity traded as Aptorum Group Limited out of 17 Hanover Square, London. Huen signed the September 4 filing in his capacity as chief executive. Full agreement texts appear as Exhibits 10.1 and 10.2.